Cencora Inc. (COR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cencora Inc. (COR) has a cash flow conversion efficiency ratio of 0.373x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.34 Billion) by net assets ($3.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cencora Inc. balance sheet quality to measure how much of total assets are equity-financed.
Cencora Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Cencora Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cencora Inc. (COR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Cencora Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cencora Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sandvik AB
ST:SAND
|
0.046x |
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SHE:002384
|
0.020x |
|
Electronic Arts Inc
NASDAQ:EA
|
0.086x |
|
Nike Inc
NYSE:NKE
|
0.031x |
|
AutoZone Inc
NYSE:AZO
|
-0.128x |
|
Edwards Lifesciences Corp
NYSE:EW
|
0.004x |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
N/A |
|
Discover Financial Services
NYSE:DFS
|
0.112x |
Annual Cash Flow Conversion Efficiency for Cencora Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Cencora Inc. from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see COR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.75 Billion | $3.88 Billion | 2.218x | -49.92% |
| 2024-09-30 | $786.74 Million | $3.48 Billion | 4.429x | -24.55% |
| 2023-09-30 | $666.29 Million | $3.91 Billion | 5.870x | -84.52% |
| 2022-09-30 | $71.27 Million | $2.70 Billion | 37.926x | +731.19% |
| 2021-09-30 | $584.41 Million | $2.67 Billion | 4.563x | +273.59% |
| 2020-09-30 | $-839.64 Million | $2.21 Billion | -2.629x | -403.40% |
| 2019-09-30 | $2.71 Billion | $2.34 Billion | 0.866x | +65.84% |
| 2018-09-30 | $2.70 Billion | $1.41 Billion | 0.522x | -27.57% |
| 2017-09-30 | $2.06 Billion | $1.49 Billion | 0.721x | -52.77% |
| 2016-09-30 | $2.08 Billion | $3.18 Billion | 1.527x | -84.83% |
| 2015-09-30 | $389.56 Million | $3.92 Billion | 10.064x | +1245.96% |
| 2014-09-30 | $1.96 Billion | $1.46 Billion | 0.748x | +120.07% |
| 2013-09-30 | $2.32 Billion | $788.12 Million | 0.340x | -36.06% |
| 2012-09-30 | $2.46 Billion | $1.31 Billion | 0.531x | +30.43% |
| 2011-09-30 | $2.87 Billion | $1.17 Billion | 0.407x | +8.56% |
| 2010-09-30 | $2.95 Billion | $1.11 Billion | 0.375x | +30.06% |
| 2009-09-30 | $2.72 Billion | $783.76 Million | 0.289x | +6.08% |
| 2008-09-30 | $2.71 Billion | $737.07 Million | 0.272x | -30.21% |
| 2007-09-30 | $3.10 Billion | $1.21 Billion | 0.390x | +99.90% |
| 2006-09-30 | $4.14 Billion | $807.26 Million | 0.195x | -45.34% |
| 2005-09-30 | $4.28 Billion | $1.53 Billion | 0.357x | +87.57% |
| 2004-09-30 | $4.34 Billion | $825.08 Million | 0.190x | +114.65% |
| 2003-09-30 | $4.01 Billion | $354.81 Million | 0.089x | -45.18% |
| 2002-09-30 | $3.32 Billion | $535.93 Million | 0.162x | +1246.68% |
| 2001-09-30 | $2.84 Billion | $-40.00 Million | -0.014x | -101.84% |
| 2000-09-30 | $282.29 Million | $216.58 Million | 0.767x | +4152.92% |
| 1999-09-30 | $166.30 Million | $3.00 Million | 0.018x | -98.92% |
| 1998-09-30 | $75.30 Million | $125.90 Million | 1.672x | +357.09% |
| 1997-09-30 | $14.30 Million | $-9.30 Million | -0.650x | +40.17% |
| 1996-09-30 | $-36.80 Million | $40.00 Million | -1.087x | -514.33% |
| 1995-09-30 | $-135.70 Million | $-35.60 Million | 0.262x | +193.91% |
| 1994-09-30 | $-300.70 Million | $84.00 Million | -0.279x | -- |
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order … Read more